Clovis Oncology Inc.’s (NASDAQ: CLVS) shares moved in a downward direction Friday afternoon, after presenting comprehensive dataset from successful Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer at the ESMO 2017.
A release issued Thursday showed the company, based out of Boulder, Colorado, told a conference in Madrid its ARIEL3 study successfully achieved its primary endpoint and key secondary endpoint, demonstrating improved progression-free survival (PFS) by both investigator review and blinded independent central review in each of the three populations studied.
CEO Patrick Mahaffy was quoted as saying, “Very importantly, this benefit was demonstrated across all three ARIEL3 populations by both investigator review and blinded independent central assessment, including among women whose cancer does not exhibit a BRCA mutation or homologous recombination deficiency.
“In particular, ARIEL3 shows 13.7 months – well over a year – of median PFS in the all-comers population in the trial as determined by blinded independent review, which we believe could be extremely important for women battling this difficult disease.
ARIEL3 is a double-blind, placebo-controlled, phase 3 trial of rucaparib that enrolled 564 women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer.
Last December, the company’s Rubraca product became the first PARP inhibitor approved by the U.S. Food and Drug Administration (FDA) as monotherapy for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer.
Shares in Clovis stumbled $4.31, or nearly 6%, to $68.01, within a 52-week trading range of $25.35, to $99.45
